<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04695223</url>
  </required_header>
  <id_info>
    <org_study_id>ANTI-P53</org_study_id>
    <nct_id>NCT04695223</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide for Structural p53 Mutations</brief_title>
  <official_title>Targeting Structural p53 Mutations With Arsenic Trioxide for Intractable Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      TP53 is the most frequently mutated gene in cancer, but these mutations remain&#xD;
      therapeutically non-actionable. Previous study reported arsenic trioxide could rescue&#xD;
      structural p53 mutations, endowing p53 mutations with thermostability and transcriptional&#xD;
      activity. Under Vivo and Vitro experiments, arsenic trioxide could reactivate mutated p53 to&#xD;
      inhibit tumor. This trial aimed to explore the efficacy and safety of arsenic trioxide in&#xD;
      refractory cancer patients with structural p53 mutations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Evaluation of tumor burden based on RECIST criteria through study completion, an average of 2 months</time_frame>
    <description>Proportion of patients with reduction in tumor burden of a predefined amount, including complete remission and partial remission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progress Free Survival</measure>
    <time_frame>Evaluation of tumor burden based on RECIST criteria until first documented progress through study completion, an average of 2 months</time_frame>
    <description>Time from treatment beginning until disease progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of treatment beginning until the date of death from any cause, through study completion, an average of 1 months</time_frame>
    <description>Time from treatment beginning until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effect</measure>
    <time_frame>Through study completion, an average of 1 months</time_frame>
    <description>Incidence of Treatment-related adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Arsenic Trioxide</condition>
  <condition>p53 Mutations</condition>
  <condition>Refractory Cancer</condition>
  <condition>Intractable Cancer</condition>
  <arm_group>
    <arm_group_label>Arsenic Trioxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arsenic Trioxide (0.16mg/kg,d1-5,ivgtt,28days as a duration) for injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic Trioxide</intervention_name>
    <description>Refractory cancer patients without standard-of-care harboring TP53 mutation received Arsenic Trioxide Injection (0.16mg/kg,d1-5,ivgtt,28days as a duration)</description>
    <arm_group_label>Arsenic Trioxide</arm_group_label>
    <other_name>As2O3</other_name>
    <other_name>Arsenic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Malignant solid tumors diagnosed histologically;&#xD;
&#xD;
          -  Solid tumor patients have no any standard choice after multiple line of therapy;&#xD;
&#xD;
          -  Next-generation Sequence showed TP53 mutation;&#xD;
&#xD;
          -  Expected survival ≥ 1 month;&#xD;
&#xD;
          -  ECOG / PS score: 0-2, and the main organ function to meet the following criteria: HB ≥&#xD;
             90g / L, ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L,BIL &lt;1.5 times the upper limit of&#xD;
             normal (ULN); Liver ALT and AST &lt;2.5 × ULN and if liver metastases, ALT and AST &lt;5 ×&#xD;
             ULN; Serum Cr ≤ 1 × ULN, endogenous creatinine clearance ≥50ml/min&#xD;
&#xD;
          -  normal cardiac function&#xD;
&#xD;
          -  obtain informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient still has standard treatment therapy based on NCCN guidance;&#xD;
&#xD;
          -  Patient can not comply with research program requirements or follow-up;&#xD;
&#xD;
          -  woman who are pregnant or breastfeeding;&#xD;
&#xD;
          -  allergic to any drug in protocol or with contraindications;&#xD;
&#xD;
          -  cannot understand or obey the protocol;&#xD;
&#xD;
          -  with a history of allergies or intolerability;&#xD;
&#xD;
          -  participate in other clinical trials meanwhile;&#xD;
&#xD;
          -  any situations that hinder trial existed;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Medical Oncology, Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaodong Jiao</last_name>
      <phone>+86-13817797639</phone>
      <email>13817797639@139.com</email>
    </contact>
    <investigator>
      <last_name>Yuan-Sheng Zang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 1, 2021</study_first_submitted>
  <study_first_submitted_qc>January 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Yuan-Sheng Zang</investigator_full_name>
    <investigator_title>Department Director</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

